A Novel Immunotherapy: LYC-55716, a Small-molecule ROR gamma Agonist, in Clinical Trials for Head and Neck Squamous Cell Carcinoma

Hu X.; Liu X.; Li H.; Bogdan M.; Gao Y.; Fox B.; Weems G.; Wilkins H. J.; Carter L.

首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >A Novel Immunotherapy: LYC-55716, a Small-molecule ROR gamma Agonist, in Clinical Trials for Head and Neck Squamous Cell Carcinoma

【24h】

A Novel Immunotherapy: LYC-55716, a Small-molecule ROR gamma Agonist, in Clinical Trials for Head and Neck Squamous Cell Carcinoma

机译：一种新型免疫疗法：LYC-55716，一种小分子RORγ激动剂，用于头部和颈部鳞状细胞癌的临床试验中

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《International Journal of Radiation Oncology, Biology, Physics》 |2018年第5期|共1页
作者
Hu X.; Liu X.; Li H.; Bogdan M.; Gao Y.; Fox B.; Weems G.; Wilkins H. J.; Carter L.;
展开▼
作者单位

Lycera Corp Ann Arbor MI USA;

Lycera Corp Ann Arbor MI USA;

Lycera Corp Ann Arbor MI USA;

Lycera Corp Ann Arbor MI USA;

Lycera Corp Ann Arbor MI USA;

Celgene Corp Seattle WA USA;

Lycera Corp Plymouth Meeting PA USA;

Lycera Corp Plymouth Meeting PA USA;

Lycera Corp Ann Arbor MI USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;
关键词

相似文献

外文文献
中文文献
专利

1. A Novel Immunotherapy: LYC-55716, a Small-molecule ROR gamma Agonist, in Clinical Trials for Head and Neck Squamous Cell Carcinoma [J] . Hu X., Liu X., Li H., International Journal of Radiation Oncology, Biology, Physics . 2018,第5期

机译：一种新型免疫疗法：LYC-55716，一种小分子RORγ激动剂，用于头部和颈部鳞状细胞癌的临床试验中
2. Expression of Oct3/4 and Nanog in the head and neck squamous carcinoma cells and its clinical implications for delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma [J] . Noboru Habu, Yorihisa Imanishi, Kaori Kameyama, BMC Cancer . 2015,第1期

机译：口头鳞状细胞癌中头颈部鳞状细胞癌中Oct3 / 4和Nanog的表达及其对延迟颈部转移的临床意义
3. Phase I trial of DNA-hsp65 immunotherapy for advanced squamous cell carcinoma of the head and neck [J] . P Michaluart, K A Abdallah, F D Lima, Cancer gene therapy . 2008,第10期

机译：DNA-hsp65免疫疗法治疗晚期头颈部鳞状细胞癌的I期试验
4. Up-Regulation of Enhancer of Zeste Homolog 2 Is Associated Positively With Cyclin Dl Overexpression and Poor Clinical Outcome in Head and Neck Squamous Cell Carcinoma [C] . Wei Cao, Zhien Feng, Zhibin Cui, Academic Committee conference of Shanghai key lab of stomatology . 2011

机译：Zeste同源2的增强子的上调与Cyclin Dl过度表达和头颈部鳞状细胞癌的不良临床结果呈正相关。
5. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. [D] . 野﨑, 結 2019

机译：PD-L1特异性辅助性T细胞表现出有效的抗肿瘤反应：针对头颈部鳞状细胞癌中PD-L1的癌症免疫疗法的新策略。
6. Combining Radiotherapy and Immunotherapy in Definitive Treatment of Head and Neck Squamous Cell Carcinoma: Review of Current Clinical Trials [O] . Assist. Gaber Plavc, Primoz Strojan 2020

机译：结合放疗和免疫疗法在头颈鳞状细胞癌的明确治疗：目前临床试验综述
7. Expression of Oct3/4 and Nanog in the head and neck squamous carcinoma cells and its clinical implications for delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma [O] . Noboru Habu, Yorihisa Imanishi, Kaori Kameyama, 2015

机译：口头鳞状细胞癌中头颈部鳞状细胞癌中Oct3 / 4和Nanog的表达及其对延迟颈部转移的临床意义

A Novel Immunotherapy: LYC-55716, a Small-molecule ROR gamma Agonist, in Clinical Trials for Head and Neck Squamous Cell Carcinoma

著录项

相似文献

相关主题

期刊订阅